News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lupin Ltd. (LUPN.BO) in $58 Million Licensing Pact with Medicis (MRX)


7/25/2011 7:58:02 AM

Drugmaker Lupin said on Monday it has signed a pact with US-based Medicis Pharmaceutical Corp to develop multiple therapeutic compounds using the former’s formulation technologies. Lupin would receive an up front payment of $20 million from the US based Medicis in addition to various milestone payments of up to $38 million, the Indian company said in a statement. Medicis would have global exclusive rights for the products developed under the agreement. Lupin would receive single digit royalty on sales achieved by Medicis and hold marketing rights in India, it said.

Read at Live Mint
Read at News Release
Read at EconomicTimes
Read at Money Control


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES